Mineral changes in osteoporosis: a review.
Bone mineral composition, crystallinity, and bone mineral content of osteoporotic patients are different from those of normal subjects. We review the evidence that these mineralization parameters contribute to the strength (fracture resistance) of bone and the methods that have been used to examine them. A specific example is provided from analysis of biopsies from the Multiple Outcomes in Raloxifene Evaluation trial. For the analyses, randomly selected biopsies from placebo, low-dose, and high-dose groups (n = 5 per group) obtained at time zero and 2 years after treatment were examined by infrared imaging spectroscopy. In all cases, comparable increases in mineral content were found, but there were no significant variations in mineral crystallinity.
Faibish
Dan
D
Musculoskeletal Integrity Program, Hospital for Special Surgery, New York, NY 10021, USA.
Ott
Susan M
SM
Boskey
Adele L
AL
D000818:Animals; D001706:Biopsy; D015519:Bone Density / Q000502:physiology*; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008903:Minerals / Q000378:metabolism*; D010024:Osteoporosis / Q000378:metabolism* / Q000473:pathology; D013057:Spectrum Analysis
D008903:Minerals